PLoS Medicine (Aug 2021)

Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study.

  • Jocelyn Chan,
  • Heather F Gidding,
  • Christopher C Blyth,
  • Parveen Fathima,
  • Sanjay Jayasinghe,
  • Peter B McIntyre,
  • Hannah C Moore,
  • Kim Mulholland,
  • Cattram D Nguyen,
  • Ross Andrews,
  • Fiona M Russell

DOI
https://doi.org/10.1371/journal.pmed.1003733
Journal volume & issue
Vol. 18, no. 8
p. e1003733

Abstract

Read online

BackgroundThere is limited empiric evidence on the coverage of pneumococcal conjugate vaccines (PCVs) required to generate substantial indirect protection. We investigate the association between population PCV coverage and indirect protection against invasive pneumococcal disease (IPD) and pneumonia hospitalisations among undervaccinated Australian children.Methods and findingsBirth and vaccination records, IPD notifications, and hospitalisations were individually linked for children aged ConclusionsIn this study, we observed substantial indirect protection at lower levels of PCV coverage than previously described-challenging assumptions that high levels of PCV coverage (i.e., greater than 90%) are required. Understanding the association between PCV coverage and indirect protection is a priority since the control of vaccine-type pneumococcal disease is a prerequisite for reducing the number of PCV doses (from 3 to 2). Reduced dose schedules have the potential to substantially reduce program costs while maintaining vaccine impact.